ONKOLOGIE www.onkologiecs.cz 82 MONOKLONÁLNÍ GAMAPATIE PŘEHLED PŘÍNOSU DARATUMUMABU PRO LÉČBU VŠECH MONOKLONÁLNÍCH GAMAPATIÍ, ALE I DALŠÍCH NEMOCÍ A VLASTNÍ ZKUŠENOSTI S LÉČBOU 74 PACIENTŮ DARATUMUMABEM, LENALIDOMIDEM A DEXAMETAZONEM for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Interní Med J. 2014;44(12b):1350-1363. doi: 10.1111/imj.12599. 243. Fei N, Shah N, Cumpston A, et al. Low-Dose Acyclovir Prophylaxis for Varicella zoster. Reactivation in Autologous Hematopoietic Cell Transplantation Recipients. Clin Hematol Int. 2019;1(2):101-104. doi: 10.2991/chi.d.190329.001. 244. Wada-Shimosato Y, Tanoshima R, Hiratoko K, et al. Effectiveness of acyclovir prophylaxis againstvaricella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Transpl Infect Dis. 2019;21(3):e13061. doi: 10.1111/tid.13061. 245. Drgona L, Gudiol C, Lanini S, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II): CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl 2):S83-S94. doi: 10.1016/j.cmi.2018.03.022. 246. Khan S, Vaisman A, Hota SS, Bennett S, Trudel S, Reece D, Tiedemann RE. Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. JAMA Oncol. 2020;6(2):293-294. doi: 10.1001/jamaoncol.2019.5098. 247. Nakagawa R, Onishi Y, Kawajiri A, et al. Preemptive therapy for cytomegalovirus reactivation after daratumumab- -containing treatment in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2019;98(8):1999-2001. doi: 10.1007/s00277-019-03645-7. 248. Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34(8):2000-2011. doi: 10.1038/ s41375-020-0876-z. 249. Kuzume A, Tabata R, Terao T, et al. Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure. Br J Haematol. 2021;193(4):e33-e36. doi: 10.1111/bjh.17412. 250. Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018;103(6):e277-e278. doi:10.3324/haematol.2018.191122. 251. Jeyaraman P, Bhasin A, Dayal N, et al. Daratumumab in dialysis-dependent multiple myeloma. Blood Res. 2020;55(1):65-67. doi: 10.5045/br.2020.55.1.65. 252. Saengsirinavin AO, Wutthayakorn W, Chansangpetch S, et al. Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion. Am J Ophthalmol Case Rep. 2021;22:101079. doi:10.1016/j.ajoc.2021.101079. 253. Nadeau Nguyen M, Chambers W, Dores GM, et al. Association of Daratumumab Use With Ocular Events in a Case Series of US Adults. JAMA Oncol. e221634. doi: 10.1001/jamaoncol.2022.1634. 254. Cho J, Siegel N, Subramanian ML, et al. Rapidly progressive neovaskular glaucoma from cytomegalovirus retinitis in non-human immunodeficiency virus patient. Retin Cases Brief Rep. 2021;15(1):62-64. doi: 10.1097/ICB.0000000000000734. 255. Minařík J, Novák J, Flodr P, et al. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. European journal of haematology. 2017;99(2):186-189. 256. Nijhof IS, Casneuf T, Van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, Am J Hematol. 2016;128:959-970. 257. Saltarella I, Desantis V, Melaccio A, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9(1):167-170. 258. Wang Y, Zhang Y, Hughes T, et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin Cancer Res. 2018;24:4006-4017. 259. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rit- uximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699-713. 260. Rendtlew Danielsen JM, Knudsen LM, Dahl IM, et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol. 2007;138:756-760. 261. Syed YY. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Drugs. 2019;79(4):447-454. doi: 10.1007/s40265019-01080-6. 262. Bapatla A, Kaul A, Dhalla PS, et al. Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma. Cureus. 2021;13(6):e15440. doi: 10.7759/cureus.15440. 263. Lamb YN. Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. Drugs. 2020;80(14):1455-1464. doi: 10.1007/s40265020-01385-x.
RkJQdWJsaXNoZXIy NDA4Mjc=